Spanish biopharmaceutical company Laboratoris Sanifit has appointed Alexander Gold as chief medical officer and president of its US subsidiary.
He joins the Palma-headquartered company from Portola Pharmaceuticals, where he served as a senior vice president and head of clinical development.
Sanifit’s CEO Joan Perelló said, “We are very happy to have Dr Gold join our leadership team. Alex arrives here with first class operational and clinical development expertise in novel drug therapies, targeting cardiovascular and metabolic disease and kidney disease amongst others.
“In addition, his work in regulatory and medical affairs will be invaluable as we continue to take our novel clinical programmes through to approval.”
A cardiologist with over 16 years experience of drug development, Dr Gold is also an adjunct professor at Stanford University School of Medicine and has held various pharma leadership.
Prior to his time at Portola, Dr Gold was head of clinical development at Reata Pharmaceuticals and before that spent 11 years at AstraZeneca.
Sanifit, which focused on treatments for calcification disorders, was founded in 2007 as a spin-off of the University of the Balearic Islands and opened its first US office in San Diego in 2016.